oestrogen receptor assay evaluation in breast cancer. Oestrogen receptor assays on cytosol preparations from malignant tissue are valuable for prognosis and for selecting patients with breast cancer for endocrine treatment. '13 Steroid receptors are routinely measured with radiolabelled ligands through their specific binding function. Enzyme immunoassays using monoclonal antibodies that recognise determinants on the receptor protein have also recently been applied to assess oestrogen receptor concentrations in cytosol or nuclear fractions of breast cancer biopsy specimens.4' Oestrogen receptor assays on cytosols, however, do not have an optimal predictive value. A positive cytosol oestrogen receptor assay does not guarantee a positive response to oestrogen therapy: only 60% of the oestrogen receptor positive patients benefit from endocrine treatment. On the other hand, prediction of response to hormone treatment is more reliable for patients with oestrogen receptor negative tumours of whom only about 10% react favourably.'2 The heterogeneous nature of most breast cancer specimens Accepted for publication 13 January 1988 is presumably one of the main factors responsible for the limited predictive value of receptor assays on homogenised tissue, and highly variable oestrogen receptor concentrations within a biopsy specimen have been found.7"2 In many cases of oestrogen receptor analysis the tissue composition that is, the relative amount of connective tissue, normal tissue, or necrosis of malignant tissue-is unknown. As the receptor content is expressed in fmol/mg of protein, this may be an important source of errors.7 0 11 1314 Assays of tissue sections could overcome some of the limitations of oestrogen receptor assays in homogenised neoplastic tissues.'"'8 We developed a radiochemical oestrogen receptor assay on cryostat sections of target tissues, which permits Scatchard analysis of both soluble and section bound oestrogen receptor on relatively small samples (50-80 mg of tissue).'9 With this technique, parallel sections can be used to verify tissue composition or to perform histochemical and immunohistochemical correlative studies.
The development of specific anti-oestrogen receptor 623 Scheres, De Goeij, Rousch, Hondius, Willebrand, Gijzen, Bosman monoclonal antibodies has permitted the visualisation of oestrogen receptor with immunohistochemical techniques,202' and several published reports describe the semi-quantification of the immunohistochemical reaction.22 24A correlative study was recently reported in which oestrogen receptor immunohistochemical analysis and a radioligand binding assay on adjacent breast cancer sections were applied, 25 In a similar study we compared an oestrogen receptor assay with radiolabelled oestradiol and semi-quantitative histochemical detection with a monoclonal antibody using parallel cryostat sections of breast cancer tissue.
Material and methods

TISSUE SAMPLES
Tissue samples from 50 surgically removed primary breast carcinomas were selected and histologically typed in the surgical pathology division of our department. Immature bovine uterus was used as standard tissue for the radiochemical oestrogen receptor section assay. The tissue samples were rapidly frozen in isopentane cooled with dry ice (-70°C) and stored at -800 C.
Each tumour block was divided into five adjacent parts. The first two parts were used for diagnostic purposes. The third and fifth part were homogenised for the preparation of cytosol; the fourth part, adjacent to the blocks for the cytosol assay, was used for the preparation of cryostat sections. Oestrogen receptor score = I P(i) x i, where i=O i = intensity of staining (0-4) and P(i) = percentage of stained tumour cells in category i (0-100%).
The classification of the staining intensity was assessed on at least three separate cohorts of 100 tumour cells from each tumour ofdifferent high power 625 (x 400) fields, which allowed heterogeneity in tumour cell receptor content to be assessed. Scoring was performed by two pairs of independent observers working without prior knowledge of the cytosol oestrogen receptor content. Before scoring of the breast cancer sample the observer pairs reached a consensus on classification by using the reference preparation included in the oestrogen receptor-ICA kit. The final oestrogen receptor score of the sample was obtained by calculating the mean of all scores. shows the presence of oestrogen receptors, characterised by saturable and high affinity binding of oestradiol (dissociation constant kd = 0-05-1 -0 nM). The reproducibility of this assay was determined by multiple assays (n = 9) on calf uterus, and the interassay variation for oestrogen receptor determination Classification of the 50 samples into oestrogen receptor positive and negative breast cancers, as determined with both assays, is shown in table 1 immunocytochemically oestrogen receptor positive tumours. Staining was heterogeneously distributed over the malignant cells in most breast cancer samples. Adjacent epithelial cells of normal breast tissue also often showed nuclear staining. In at least three fields of each section, each field including 100 cells, the nuclear staining was classified into five categories ranging from no (0) to very intense (4) staining and an oestrogen receptor score was obtained as detailed. To facilitate comparison of immunohistochemical and radiochemical results only the total oestrogen receptor scores are presented. It is important to note, however, that significant differences often occurred between the fields.
Results
COMPARISON OF RADIOCHEMICAL DETECTION OF OESTROGEN RECEPTOR
The intraobserver variability for visual assessment of the oestrogen receptor score was studied. Cases negative by radioligand binding assay but positive by immunohistochemical assay may be due to methodological errors in the radioligand assay or to dilution of cytosol with oestrogen receptor negative material in samples with a low oestrogen receptor positive cell content. Cases negative by immunohistochemical assay but positive by radioligand assay may be due to the methodological difference between detecting a molecule through antigen-antibody bind-ing and receptor-ligand binding, although the monoclonal anti-oestrogen receptor antibody recognised an epitope that is distinct from the oestradiol binding site of the receptor. Furthermore, admixture of oestrogen receptor positive, non-neoplastic cells, which are not taken into account in the immunohistochemical oestrogen receptor score, may be responsible. Similar discrepancies between immunohistochemical and radioligand binding assay have been reported.3536 Whether breast cancers with negative oestrogen receptor scores belong to the group of non-responders to endocrine treatment in the cytosol oestrogen receptor positive group of breast cancer patients, as has been reported earlier,36 has to be verified. Final validation of semiquantitative immunohistochemical oestrogen receptor assay for clinical use awaits assessment of its ability to predict the response to hormonal treatment and the prognosis.
Semiquantitative analysis, resulting in a single number score, does not take into account the possibility that heterogeneity may contain important biological information. We feel that the distribution pattern of the staining intensity of the tumour cells should be separately analysed in relation to clinical data. In this respect, the ability to show the presence of oestrogen receptor in paraffin sections is important. Some attempts have been reported37" but as yet no validated techniques for routinely fixed malignant tissue have been described.
In conclusion, we have shown that cryostat sections of breast cancer can be used for radiochemical oestrogen receptor assay, and that the radiochemical section assay is a reliable and reproducible technique, which offers advantages over the use of cytosol. The semiquantitative immunohistochemical oestrogen receptor score correlates better with radiochemical assay on sections compared with cytosol. The results indicate that oestrogen receptors may be reliably quantitated by semiquantitative evaluation of specific immunostaining in cryostat sections of human breast cancer, but only if this technique is adequately standardised.
